Vb-201

Published

dm+d

Unassigned

New Medicines

Psoriasis - moderate to severe plaque

Information

New molecular entity
VBL Therapeutics
VBL Therapeutics

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Feb 15: VBL Therapeutics announces that its PII studies evaluating VB-201 in patients with psoriasis and ulcerative colitis did not meet their primary endpoints. VBL does not plan to continue development of VB-201 in these indications [3].

Category

first-in-class, orally-available, specific innate immunity disease-modifying medicine from a series of proprietary oxidized phospholipid analogues
20 March 2012Psoriasis affects approx 2% of Europeans, with 90% of these having plaque psoriasis. Peaks in late teens and again in middle age. [2]
Psoriasis - moderate to severe plaque
Oral